ADC Therapeutics SA

NYSE:ADCT

2.7 (USD) • At close September 6, 2024
Bedrijfsnaam ADC Therapeutics SA
Symbool ADCT
Munteenheid USD
Prijs 2.7
Beurswaarde 260,948,250
Dividendpercentage 0%
52-weken bereik 0.36 - 6.04
Industrie Biotechnology
Sector Healthcare
CEO Dr. Ameet Mallik M.B.A., M.S.
Website https://www.adctherapeutics.com

An error occurred while fetching data.

Over ADC Therapeutics SA

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical

Vergelijkbare Aandelen

Butterfly Network, Inc. logo

Butterfly Network, Inc.

BFLY

1.64 USD

Owlet, Inc. logo

Owlet, Inc.

OWLT

4.31 USD

Vicarious Surgical Inc. logo

Vicarious Surgical Inc.

RBOT

5.77 USD

ATI Physical Therapy, Inc. logo

ATI Physical Therapy, Inc.

ATIP

5.95 USD

Community Health Systems, Inc. logo

Community Health Systems, Inc.

CYH

5.7 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)